Mechanistic remodeling and immunoregulatory functions of the B cell–humoral immunity axis in inflammatory bowel disease
Open Access
- 9 July 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1857614
Abstract
Inflammatory bowel disease (IBD) is an immune-mediated disorder characterized by chronic inflammation of the intestinal mucosa, arising from dysregulation across multiple layers of immune control. In recent years, the contribution of B cells and humoral immunity to IBD pathogenesis has gained increasing attention. B cells participate in mucosal immune regulation through differentiation, clonal expansion, and antibody production, and are closely associated with the formation and structural organization of local tertiary lymphoid structures (TLSs). Beyond antigen neutralization, antibodies can modulate inflammatory cell activation and tissue injury via Fc receptor signaling, complement activation, and immune complex–mediated responses. In parallel, intestinal barrier integrity and the extent of antigen exposure critically influence B cell activation and antibody output, forming an interconnected network of local immune processes. Therapeutic strategies targeting the B cell–humoral immunity axis are emerging, including B cell–directed therapies, modulation of antibody effector pathways, and restoration of mucosal immune function. Although accumulating evidence suggests that these approaches may confer benefits in controlling inflammation and modulating immune responses, their efficacy and applicability vary across different strategies and patient populations. In this review, we systematically integrate current evidence on B cell differentiation, local lymphoid organization, and humoral immune responses in IBD. We propose the “B cell–humoral immunity regulatory axis” as a conceptual framework to delineate mucosal immune remodeling in IBD, with the aim of advancing mechanistic understanding and informing the optimization of therapeutic interventions.Keywords
This publication has 154 references indexed in Scilit:
- Distinct clinicopathological features of IgA nephropathy associated with Crohn’s disease: comparison with ulcerative colitis and non-IBD IgA nephropathyClinical and Experimental Nephrology, 2026
- The Antibody‐Microbiota Interface in Autoimmune DiseasesMuscle & Nerve, 2026
- Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein AProtein Science, 2025
- Action of the Terminal Complement Pathway on Cell MembranesThe Journal of Membrane Biology, 2025
- Serological Markers as Predictors of Anti-TNF Response in Children with Crohn’s DiseaseDigestive Diseases and Sciences, 2024
- Role of mucosal IgA antibodies as novel therapies to enhance mucosal barriersSeminars in Immunopathology, 2024
- Characterization of novel CD8+ regulatory T cells and their modulatory effects in murine model of inflammatory bowel diseaseCellular and Molecular Life Sciences, 2024
- Mouse IgA modulates human gut microbiota with inflammatory bowel disease patientsJournal of Gastroenterology, 2024
- Landscape of gut mucosal immune cells showed gap of follicular or memory B cells into plasma cells in immunological non‐respondersClinical and Translational Medicine, 2024
- Identification of antigen-presentation related B cells as a key player in Crohn’s disease using single-cell dissecting, hdWGCNA, and deep learningClinical and Experimental Medicine, 2023